Skip to content

Testing Calcarea Carb to help manage dyslipidemia in people with type 2 diabetes mellitus of Bhavnagar

To evaluate the role of Calcarea Carbonica 30C as an adjuvant to the standard therapy for dyslipidemic patients of type 2 diabetes mellitus in Bhavnagar, Gujarat - NIL

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/11/097589
Enrollment
120
Registered
2025-11-17
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E116- Type 2 diabetes mellitus with other specified complications

Interventions

Intervention1: Calcarea Carbonica: 4 globules of 30 number of 30C potency, daily at night for 12 weeks Control Intervention1: Placebo: 4 globules of 30 number, daily at night for 12 weeks

Sponsors

Khushbu Navadia
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Participants diagnosed as diabetic based on clinical history, biochemical markers and/or use of oral hypoglycemic agents (OHA) 2. Participants diagnosed as dyslipidemic based on biochemical markers and/or taking any anti-dyslipidemic medicine including statins 3. Participant of any gender 4. Participants in the age group 19 years to 70 years

Exclusion criteria

Exclusion criteria: 1. Participants who are already on Homoeopathic medicines and do not wish to discontinue their ongoing treatment 2. Pregnant and lactating mothers 3. Participants not willing to give their consent

Design outcomes

Primary

MeasureTime frame
Change in total serum Cholesterol (mg/dL)Timepoint: At the end of 12 weeks

Secondary

MeasureTime frame
1) Change in High Density Lipoprotein Cholesterol (mg/dL) 2) Change in Low Density Lipoprotein Cholesterol (mg/dL) 3) Change in serum Triglycerides (mg/dL) 4) Change in fasting blood sugar (mg/dL) 5) Change in glycated hemoglobin (%) 6) Change in body weight (kg) 7) Change in blood pressure (mmHg)Timepoint: At the end of 12 weeks

Countries

India

Contacts

Public ContactKhushbu Navadia

P P Savani University

zameerrefai@gmail.com9824199910

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 29, 2026